Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
INTERVENTIONAL
Inicio: 2 de mar de 2006
ID: NCT00338286
Completado
Fase 3
ClinicalTrials.gov
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
INTERVENTIONAL
Inicio: 6 de ene de 2018
ID: NCT03337724
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
INTERVENTIONAL
Inicio: 23 de jun de 2015
ID: NCT02425891
Completado
Fase 3
ClinicalTrials.gov
Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects
INTERVENTIONAL
Inicio: 1 de abr de 2009
ID: NCT00914693
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
INTERVENTIONAL
Inicio: 24 de jul de 2020
ID: NCT04494425
Reclutando
Fase 3
ClinicalTrials.gov
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)
INTERVENTIONAL
Inicio: 6 de ene de 2025
ID: NCT06760637
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
INTERVENTIONAL
Inicio: 19 de ene de 2026
ID: NCT07216703
Activo, no recluta
Fase 3
ClinicalTrials.gov
PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
INTERVENTIONAL
Inicio: 26 de feb de 2020
ID: NCT03937154
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 27 de ago de 2012
ID: NCT01663727
Completado
Fase 2
ClinicalTrials.gov
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion
INTERVENTIONAL
Inicio: 30 de sept de 2015
ID: NCT02576431
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
INTERVENTIONAL
Inicio: 28 de ago de 2017
ID: NCT03207867
Completado
Fase 2
ClinicalTrials.gov
Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine
INTERVENTIONAL
Inicio: 1 de ago de 2004
ID: NCT00087958
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
INTERVENTIONAL
Inicio: 30 de mar de 2020
ID: NCT04246489
Completado
ClinicalTrials.gov
A Multicenter Retrospective Study on the Prognostic Impact of Pregnancy in Women With History of BRCA Mutated Breast Cancer
OBSERVATIONAL
Inicio: 16 de ene de 2017
ID: NCT03673306
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b, Non-randomized, Open Label, Multi-country, Cohort Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) During Any Pregnancy Conceived Post Vaccination/Control
INTERVENTIONAL
Inicio: 7 de feb de 2023
ID: NCT05705440
Reclutando
ClinicalTrials.gov
Validation of the Oncoliq Test for the Early Detection of Breast Cancer.
OBSERVATIONAL
Inicio: 17 de oct de 2025
ID: NCT07331506
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer
INTERVENTIONAL
Inicio: 11 de ene de 2018
ID: NCT03371017
Reclutando
Fase 3
ClinicalTrials.gov
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
INTERVENTIONAL
Inicio: 1 de ago de 2024
ID: NCT06380751
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease
INTERVENTIONAL
Inicio: 14 de oct de 2020
ID: NCT04478266
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
INTERVENTIONAL
Inicio: 28 de jun de 2021
ID: NCT04915755
Anterior
1
...
15
16
17
...
434
Siguiente
Filtros